315 related articles for article (PubMed ID: 25564255)
21. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.
Dou S; Yang XZ; Xiong MH; Sun CY; Yao YD; Zhu YH; Wang J
Adv Healthc Mater; 2014 Nov; 3(11):1792-803. PubMed ID: 24947820
[TBL] [Abstract][Full Text] [Related]
22. Development of
Rainone P; Riva B; Belloli S; Sudati F; Ripamonti M; Verderio P; Colombo M; Colzani B; Gilardi MC; Moresco RM; Prosperi D
Int J Nanomedicine; 2017; 12():3447-3461. PubMed ID: 28496321
[TBL] [Abstract][Full Text] [Related]
23. PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity.
Gao J; Kou G; Wang H; Chen H; Li B; Lu Y; Zhang D; Wang S; Hou S; Qian W; Dai J; Zhao J; Zhong Y; Guo Y
Breast Cancer Res Treat; 2009 May; 115(1):29-41. PubMed ID: 18481173
[TBL] [Abstract][Full Text] [Related]
24. Targeted Therapy in HER2-Positive Breast Cancer.
Thill M; Kraft C; Friedrich M
Oncol Res Treat; 2016; 39(5):295-302. PubMed ID: 27173915
[TBL] [Abstract][Full Text] [Related]
25. Advances in novel drug delivery strategies for breast cancer therapy.
Dhankhar R; Vyas SP; Jain AK; Arora S; Rath G; Goyal AK
Artif Cells Blood Substit Immobil Biotechnol; 2010 Oct; 38(5):230-49. PubMed ID: 20677900
[TBL] [Abstract][Full Text] [Related]
26. (-)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo.
Siddique AB; Ebrahim HY; Akl MR; Ayoub NM; Goda AA; Mohyeldin MM; Nagumalli SK; Hananeh WM; Liu YY; Meyer SA; El Sayed KA
Nutrients; 2019 Feb; 11(2):. PubMed ID: 30781364
[TBL] [Abstract][Full Text] [Related]
27. HER2-mediated anticancer drug delivery: strategies to prepare targeting ligands highly specific for the receptor.
Calce E; Monfregola L; Saviano M; De Luca S
Curr Med Chem; 2015; 22(21):2525-38. PubMed ID: 25994863
[TBL] [Abstract][Full Text] [Related]
28. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
29. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
30. Quantitative Study of the Interaction of Multivalent Ligand-Modified Nanoparticles with Breast Cancer Cells with Tunable Receptor Density.
Wang J; Min J; Eghtesadi SA; Kane RS; Chilkoti A
ACS Nano; 2020 Jan; 14(1):372-383. PubMed ID: 31899613
[TBL] [Abstract][Full Text] [Related]
31. A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery.
Liu Y; Li K; Liu B; Feng SS
Biomaterials; 2010 Dec; 31(35):9145-55. PubMed ID: 20864169
[TBL] [Abstract][Full Text] [Related]
32. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
33. Optimization of an anti-HER2 monoclonal antibody targeted delivery system using PEGylated human serum albumin nanoparticles.
Kouchakzadeh H; Shojaosadati SA; Tahmasebi F; Shokri F
Int J Pharm; 2013 Apr; 447(1-2):62-9. PubMed ID: 23454849
[TBL] [Abstract][Full Text] [Related]
34. Targeted anticancer therapy: overexpressed receptors and nanotechnology.
Akhtar MJ; Ahamed M; Alhadlaq HA; Alrokayan SA; Kumar S
Clin Chim Acta; 2014 Sep; 436():78-92. PubMed ID: 24836529
[TBL] [Abstract][Full Text] [Related]
35. HER2-directed therapy: current treatment options for HER2-positive breast cancer.
Ahmed S; Sami A; Xiang J
Breast Cancer; 2015 Mar; 22(2):101-16. PubMed ID: 25634227
[TBL] [Abstract][Full Text] [Related]
36. Targeted Nanocurcumin Therapy Using Annexin A2 Anitbody Improves Tumor Accumulation and Therapeutic Efficacy Against Highly Metastatic Breast Cancer.
Mukerjee A; Ranjan AP; Vishwanatha JK
J Biomed Nanotechnol; 2016 Jul; 12(7):1374-92. PubMed ID: 29336533
[TBL] [Abstract][Full Text] [Related]
37. [Her2 positive breast cancer: practices].
Campone M; Berton-Rigaud D; Bourbouloux E; Sophie S; Zanetti A; Frenel JS
Bull Cancer; 2011 Feb; 98(2):154-63. PubMed ID: 21591301
[TBL] [Abstract][Full Text] [Related]
38. Nanotechnology: An Emerging Therapeutic Option for Breast Cancer.
Hussain Z; Khan JA; Murtaza S
Crit Rev Eukaryot Gene Expr; 2018; 28(2):163-175. PubMed ID: 30055543
[TBL] [Abstract][Full Text] [Related]
39. Dual HER2-targeted approaches in HER2-positive breast cancer.
Ahn ER; Vogel CL
Breast Cancer Res Treat; 2012 Jan; 131(2):371-83. PubMed ID: 21956210
[TBL] [Abstract][Full Text] [Related]
40. HER2 targeted therapy in breast cancer...beyond Herceptin.
Pal SK; Pegram M
Rev Endocr Metab Disord; 2007 Sep; 8(3):269-77. PubMed ID: 17899385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
